Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management

Alemtuzumab CARE-MS I 5-year follow-up

(2017) Eva Havrdova et al.   NEUROLOGY

Alemtuzumab CARE-MS II 5-year follow-up

(2017) Alasdair J. Coles et al.   NEUROLOGY

2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum

(2017) Erik K. Alexander et al.   THYROID

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

(2017) David Baker et al.   JAMA Neurology

Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response

(2017) Mario Rotondi et al.   Frontiers in Endocrinology

2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

(2016) Douglas S. Ross et al.   THYROID

Autoimmune thyroid disorders

(2015) Alessandro Antonelli et al.   AUTOIMMUNITY REVIEWS

Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management

(2015) Moeber Mahzari et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

(2015) Tobias Ruck et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Graves' disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?

(2014) Anthony P. Weetman   CLINICAL ENDOCRINOLOGY

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis

(2014) Ruth Ann Marrie et al.   Multiple Sclerosis Journal

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis

(2013) Gilbert H. Daniels et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association

(2012) Jeffrey R. Garber et al.   THYROID

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

The role of thyroid autoimmunity in fertility and pregnancy

(2008) Kris Poppe et al.   Nature clinical practice. Endocrinology & metabolism